Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Figure 3 Adverse outcomes. A: No statistically significant differences were observed in rates of adverse outcomes (regardless of subsequent treatment discontinuations) were observed between originator and biosimilar cohorts (P = 0.206); B: Rates of adverse outcomes subdivided amongst each biosimilar compared to the originator control group. N-values are indicated within bars.